A new model of Cuprizone-Mediated demyelination/remyelination

Hilary H. Sachs, Kathryn K. Bercury, Daniela C. Popescu, S. Priya Narayanan, Wendy B. Macklin

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

In the central nervous system, demyelinating diseases, such as multiple sclerosis, result in devastating long-term neurologic damage, in part because of the lack of effective remyelination in the adult human brain. One model used to understand the mechanisms regulating remyelination is cuprizone-induced demyelination, which allows investigation of remyelination mechanisms in adult animals following toxin-induced demyelination. Unfortunately, the degree of demyelination in the cuprizone model can vary, which complicates understanding the process of remyelination. Previous work in our laboratory demonstrated that the Akt/mTOR pathway regulates active myelination. When given to young postnatal mice, the mTOR inhibitor, rapamycin, inhibits active myelination. In the current study, the cuprizone model was modified by the addition of rapamycin during cuprizone exposure. When administered together, cuprizone and rapamycin produced more complete demyelination and provided a longer time frame over which to investigate remyelination than treatment with cuprizone alone. The consistency in demyelination will allow a better understanding of the mechanisms initiating remyelination. Furthermore, the slower rate of remyelination provides a longer window of time in which to investigate the diverse contributing factors that regulate remyelination. This new model of cuprizone-induced demyelination could potentially aid in identification of new therapeutic targets to enhance remyelination in demyelinating diseases.

Original languageEnglish (US)
JournalASN Neuro
Volume6
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Cuprizone
Demyelinating Diseases
Sirolimus
Nervous System
Multiple Sclerosis
Central Nervous System

Keywords

  • Akt
  • Cuprizone
  • Demyelination
  • MTOR
  • Oligodendrocyte
  • Rapamycin

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Sachs, H. H., Bercury, K. K., Popescu, D. C., Narayanan, S. P., & Macklin, W. B. (2014). A new model of Cuprizone-Mediated demyelination/remyelination. ASN Neuro, 6(5). https://doi.org/10.1177/1759091414551955

A new model of Cuprizone-Mediated demyelination/remyelination. / Sachs, Hilary H.; Bercury, Kathryn K.; Popescu, Daniela C.; Narayanan, S. Priya; Macklin, Wendy B.

In: ASN Neuro, Vol. 6, No. 5, 01.01.2014.

Research output: Contribution to journalArticle

Sachs, HH, Bercury, KK, Popescu, DC, Narayanan, SP & Macklin, WB 2014, 'A new model of Cuprizone-Mediated demyelination/remyelination', ASN Neuro, vol. 6, no. 5. https://doi.org/10.1177/1759091414551955
Sachs HH, Bercury KK, Popescu DC, Narayanan SP, Macklin WB. A new model of Cuprizone-Mediated demyelination/remyelination. ASN Neuro. 2014 Jan 1;6(5). https://doi.org/10.1177/1759091414551955
Sachs, Hilary H. ; Bercury, Kathryn K. ; Popescu, Daniela C. ; Narayanan, S. Priya ; Macklin, Wendy B. / A new model of Cuprizone-Mediated demyelination/remyelination. In: ASN Neuro. 2014 ; Vol. 6, No. 5.
@article{399b933392ad45b38abb66d823863310,
title = "A new model of Cuprizone-Mediated demyelination/remyelination",
abstract = "In the central nervous system, demyelinating diseases, such as multiple sclerosis, result in devastating long-term neurologic damage, in part because of the lack of effective remyelination in the adult human brain. One model used to understand the mechanisms regulating remyelination is cuprizone-induced demyelination, which allows investigation of remyelination mechanisms in adult animals following toxin-induced demyelination. Unfortunately, the degree of demyelination in the cuprizone model can vary, which complicates understanding the process of remyelination. Previous work in our laboratory demonstrated that the Akt/mTOR pathway regulates active myelination. When given to young postnatal mice, the mTOR inhibitor, rapamycin, inhibits active myelination. In the current study, the cuprizone model was modified by the addition of rapamycin during cuprizone exposure. When administered together, cuprizone and rapamycin produced more complete demyelination and provided a longer time frame over which to investigate remyelination than treatment with cuprizone alone. The consistency in demyelination will allow a better understanding of the mechanisms initiating remyelination. Furthermore, the slower rate of remyelination provides a longer window of time in which to investigate the diverse contributing factors that regulate remyelination. This new model of cuprizone-induced demyelination could potentially aid in identification of new therapeutic targets to enhance remyelination in demyelinating diseases.",
keywords = "Akt, Cuprizone, Demyelination, MTOR, Oligodendrocyte, Rapamycin",
author = "Sachs, {Hilary H.} and Bercury, {Kathryn K.} and Popescu, {Daniela C.} and Narayanan, {S. Priya} and Macklin, {Wendy B.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1177/1759091414551955",
language = "English (US)",
volume = "6",
journal = "ASN Neuro",
issn = "1759-0914",
publisher = "Portland Press Ltd.",
number = "5",

}

TY - JOUR

T1 - A new model of Cuprizone-Mediated demyelination/remyelination

AU - Sachs, Hilary H.

AU - Bercury, Kathryn K.

AU - Popescu, Daniela C.

AU - Narayanan, S. Priya

AU - Macklin, Wendy B.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - In the central nervous system, demyelinating diseases, such as multiple sclerosis, result in devastating long-term neurologic damage, in part because of the lack of effective remyelination in the adult human brain. One model used to understand the mechanisms regulating remyelination is cuprizone-induced demyelination, which allows investigation of remyelination mechanisms in adult animals following toxin-induced demyelination. Unfortunately, the degree of demyelination in the cuprizone model can vary, which complicates understanding the process of remyelination. Previous work in our laboratory demonstrated that the Akt/mTOR pathway regulates active myelination. When given to young postnatal mice, the mTOR inhibitor, rapamycin, inhibits active myelination. In the current study, the cuprizone model was modified by the addition of rapamycin during cuprizone exposure. When administered together, cuprizone and rapamycin produced more complete demyelination and provided a longer time frame over which to investigate remyelination than treatment with cuprizone alone. The consistency in demyelination will allow a better understanding of the mechanisms initiating remyelination. Furthermore, the slower rate of remyelination provides a longer window of time in which to investigate the diverse contributing factors that regulate remyelination. This new model of cuprizone-induced demyelination could potentially aid in identification of new therapeutic targets to enhance remyelination in demyelinating diseases.

AB - In the central nervous system, demyelinating diseases, such as multiple sclerosis, result in devastating long-term neurologic damage, in part because of the lack of effective remyelination in the adult human brain. One model used to understand the mechanisms regulating remyelination is cuprizone-induced demyelination, which allows investigation of remyelination mechanisms in adult animals following toxin-induced demyelination. Unfortunately, the degree of demyelination in the cuprizone model can vary, which complicates understanding the process of remyelination. Previous work in our laboratory demonstrated that the Akt/mTOR pathway regulates active myelination. When given to young postnatal mice, the mTOR inhibitor, rapamycin, inhibits active myelination. In the current study, the cuprizone model was modified by the addition of rapamycin during cuprizone exposure. When administered together, cuprizone and rapamycin produced more complete demyelination and provided a longer time frame over which to investigate remyelination than treatment with cuprizone alone. The consistency in demyelination will allow a better understanding of the mechanisms initiating remyelination. Furthermore, the slower rate of remyelination provides a longer window of time in which to investigate the diverse contributing factors that regulate remyelination. This new model of cuprizone-induced demyelination could potentially aid in identification of new therapeutic targets to enhance remyelination in demyelinating diseases.

KW - Akt

KW - Cuprizone

KW - Demyelination

KW - MTOR

KW - Oligodendrocyte

KW - Rapamycin

UR - http://www.scopus.com/inward/record.url?scp=84940094081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940094081&partnerID=8YFLogxK

U2 - 10.1177/1759091414551955

DO - 10.1177/1759091414551955

M3 - Article

VL - 6

JO - ASN Neuro

JF - ASN Neuro

SN - 1759-0914

IS - 5

ER -